Journal ArticleDOI
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
Suresh Senan,Anthony Brade,Lu Hua Wang,Johan Vansteenkiste,Shaker R. Dakhil,Bonne Biesma,Maite Martinez Aguillo,Joachim G.J.V. Aerts,Ramaswamy Govindan,Belén Rubio-Viqueira,Conrad R. Lewanski,David R. Gandara,Hak Choy,Tony Mok,Anwar Hossain,Neill Iscoe,Joseph Treat,Andrew Koustenis,Belen San Antonio,Nadia Chouaki,Everett E. Vokes +20 more
Reads0
Chats0
TLDR
Pemetrexed-cisplatin combined with TRT followed by consolidation pemetrexe was not superior to standard chemoradiotherapy for stage III unresectable nonsquamous non-small-cell lung cancer.Abstract:
PurposeThe phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation pemetrexed, versus etoposide-cisplatin and TRT followed by nonpemetrexed doublet consolidation therapy.Patients and MethodsPatients with stage IIIA/B unresectable nonsquamous non–small-cell lung cancer randomly received (1:1) pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 intravenously every 3 weeks for three cycles plus concurrent TRT (60 to 66 Gy) followed by pemetrexed consolidation every 3 weeks for four cycles (arm A), or standard therapy with etoposide 50 mg/m2 and cisplatin 50 mg/m2 intravenously, every 4 weeks for two cycles plus concurrent TRT (60 to 66 Gy) followed by two cycles of consolidation platinum-based doublet chemotherapy (arm B). The primary objective was OS. The study was designed as a superiority trial with 80% power to detect an OS hazard ratio of 0.74 with a type 1 error of .05.ResultsEnrollment was stopped early because ...read more
Citations
More filters
Journal ArticleDOI
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch,Giorgio V. Scagliotti,James L. Mulshine,Regina Kwon,Walter J. Curran,Yi-Long Wu,Luis Paz-Ares +6 more
TL;DR: Prevention and early detection of lung cancer with an emphasis on lung cancer screening is discussed, and the importance of smoking prevention and cessation is acknowledged.
Journal ArticleDOI
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
Corinne Faivre-Finn,David Vicente,Takayasu Kurata,David Planchard,Luis Paz-Ares,Johan Vansteenkiste,David R. Spigel,Marina Chiara Garassino,Martin Reck,Suresh Senan,Jarushka Naidoo,Andreas Rimner,Yi-Long Wu,Jhanelle E. Gray,Mustafa Ozguroglu,Ki Hyeong Lee,Byoung Chul Cho,Terufumi Kato,Maike de Wit,Michael Newton,Lu Wang,P. Thiyagarajah,Scott J. Antonia +22 more
TL;DR: These updated, exploratory analyses demonstrate durable PFS and sustained OS benefit with durvalumab following CRT, and are consistent with the primary analyses.
Journal ArticleDOI
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
TL;DR: The phase III PACIFIC trial as mentioned in this paper compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy.
Journal ArticleDOI
Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)
TL;DR: The potential of SMAC mimetics as effective single agent or combinatory therapies to treat cancer is highlighted and the likely clinical implications of resistance toSMAC mimetic therapy, occasionally observed in cancer cell lines are discussed.
Journal ArticleDOI
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
David Spiegel,Corinne Faivre-Finn,Jhanelle E. Gray,David Vicente,David Planchard,Luis Paz-Ares,Johan Vansteenkiste,Marina Chiara Garassino,Rina Hui,Xavier Quantin,Andreas Rimner,Yi-Long Wu,M. Özgüroĝlu,Ki Hyeong Lee,Terufumi Kato,Maike de Wit,Takayasu Kurata,Martin Reck,Byoung Chul Cho,Suresh Senan,Jarushka Naidoo,Helen Mann,Michael Newton,Piruntha Thiyagarajah,Scott J. Antonia +24 more
TL;DR: These updated analyses demonstrate robust and sustained OS and durable PFS benefit with durvalumab after chemoradiotherapy, establishing a new benchmark for standard of care in this setting.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
TL;DR: The introduction of angiogenesis, epidermal growth factor receptor inhibitors, and other new anti-cancer agents is changing the present and future of this disease and will certainly increase the number of lung cancer survivors.
Journal ArticleDOI
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley,Rebecca Paulus,Ritsuko Komaki,Gregory A. Masters,George R. Blumenschein,Steven E. Schild,Jeffrey A. Bogart,Chen Hu,Kenneth M. Forster,Anthony M. Magliocco,V.S. Kavadi,Yolanda I. Garces,Samir Narayan,Puneeth Iyengar,Cliff G. Robinson,Raymond B. Wynn,Christopher Koprowski,Joanne Meng,Jonathan J. Beitler,Rakesh Gaur,Walter J. Curran,Hak Choy +21 more
TL;DR: Overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer was compared.
Related Papers (5)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley,Rebecca Paulus,Ritsuko Komaki,Gregory A. Masters,George R. Blumenschein,Steven E. Schild,Jeffrey A. Bogart,Chen Hu,Kenneth M. Forster,Anthony M. Magliocco,V.S. Kavadi,Yolanda I. Garces,Samir Narayan,Puneeth Iyengar,Cliff G. Robinson,Raymond B. Wynn,Christopher Koprowski,Joanne Meng,Jonathan J. Beitler,Rakesh Gaur,Walter J. Curran,Hak Choy +21 more
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
Anne Auperin,Cécile Le Péchoux,Estelle Rolland,Walter J. Curran,Kiyoyuki Furuse,Pierre Fournel,José Belderbos,Gerald H. Clamon,Hakki Cuneyt Ulutin,Rebecca Paulus,Takeharu Yamanaka,Marie-Cecile Bozonnat,Apollonia L.J. Uitterhoeve,Xiaofei Wang,Lesley A. Stewart,Rodrigo Arriagada,Sarah Burdett,Jean-Pierre Pignon +17 more
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takashi Yokoi,Alberto Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Chul Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Catherine Wadsworth,Giovanni Melillo,Haiyi Jiang,Y. Huang,Phillip A. Dennis,Mustafa Ozguroglu,Pacific Investigators +30 more
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,A. Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Cheol Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Corinne Faivre-Finn,Martin Reck,Johan Vansteenkiste,David R. Spigel,Catherine Wadsworth,Giovanni Melillo,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu +32 more